Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.
Cancer Control
; 27(1): 1073274820983013, 2020.
Article
en En
| MEDLINE
| ID: mdl-33356500
ABSTRACT
BACKGROUND:
Biliary tract cancers (BTCs) represent a heterogeneous group of aggressive solid tumors with limited therapeutic options, and include gallbladder cancer (GBC), ampulla of Vater cancer (AVC), intrahepatic cholangiocarcinoma (iCCA) and extrahepatic cholangiocarcinoma (eCCA). METHODS &RESULTS:
In the current review, we will discuss recent results of clinical trials testing targeted therapies in BRAF-mutant BTCs, with a particular focus on the recently published Phase II ROAR trial and ongoing active and recruiting clinical trials.CONCLUSIONS:
Although the extended use of molecular profiling has paved the way toward a new era in BTC management, targeted therapies are limited to iCCA so far, and the prognosis of patients with metastatic disease has substantially not changed in the last decade. In this discouraging scenario, BRAF inhibition is currently emerging as a novel treatment option in patients harboring BRAF mutations.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias del Sistema Biliar
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Colangiocarcinoma
/
Proteínas Proto-Oncogénicas B-raf
/
Inhibidores de Proteínas Quinasas
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Cancer Control
Asunto de la revista:
NEOPLASIAS
Año:
2020
Tipo del documento:
Article
País de afiliación:
Italia